Floatz logo

Chir-258

Second-line Treatment

Novartis PharmaceuticalsPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Second-line Treatment cohort.

Asset / SponsorPhaseRating
Adebrelimab
Sun Yat-sen University
Phase 2CCC
Fruquintinib
Sun Yat-sen University
Phase 2CCC
Carboplatin
Second Affiliated Hospital of Zunyi Medical University
Phase 2CCC
Toripalimab
Tianjin Medical University Cancer Institute and Hospital
Phase 1CC

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →